International Vaccine Institute strategic demand forecasting; and Sabin – communications and advocacy. Besides leading the consortium, IVI generated evidence for decision-making such as disease burden, country vaccine introduction cases and a global investment case. From 2010 to 2016, DVI operated in Brazil, Burkina Faso, Cambodia, Colombia, Gabon, India, Kenya, Thailand, and Vietnam. From 2013-2015, with funding from Germany’s Federal Ministry of Education & Research (BMBF), IVI continued support for preclinical development of dengue vaccines by Brazil’s Butantan Institute and Vietnam’s VaBiotech. After the 2016 licensure of Sanofi Pasteur’s Dengvaxia vaccine, the DVI project came to a close and its IVI staff transitioned to
Oswaldo Cruz 1900, the Federal Serum Therapy Institute destined to the production of sera and vaccines against the bubonic plague was created with Baron Pedro Afonso as director general and the young bacteriologist Oswaldo Cruz as technical director. The new institute was established in the old farm of Manguinhos at the western shores of Guanabara Bay. In 1902, Cruz accepted the office of director general of the institute and soon expanded the scope of its activities, now no longer restricted to the production of sera but also dedicated to basic and applied research and to the building of human resources. In the